First and only oral therapy approved for mild, moderate, and severe plaque psoriasis, and active PsA SEE THE DATA
Inclusion on formulary does not imply superior clinical efficacy or safety.
BSA=body surface area.
*Covered includes Covered, Covered (PA/ST), Preferred and Preferred (PA/ST) as defined by Managed Markets Insights and Technology (MMIT) data.
†Number of commercially insured plaque psoriasis lives provided is obtained from MMIT for health plans in the US. Data as of April 2023.
‡Number of commercially insured plaque psoriasis and active psoriatic arthritis lives provided is obtained from MMIT for health plans in the US. Data as of June 2023.
§86% of commercially insured patients have access to Otezla with no step edits after trying topicals for plaque psoriasis.
**Includes disease-modifying antirheumatic drug (DMARD) and bio step.
Our Amgen® SupportPlus Representatives can assist with issues around patient coverage, prior authorizations, co-pay programs, and more.
We know every patient has unique needs. And we’re here to provide financial support information and resources, regardless of their current financial situation or type of insurance they have.
Dedicated Amgen® Nurse Partners will be with your patients along the way to offer supplemental support and provide information about resources to help them access their prescribed Amgen medication.
Amgen® Nurse Partners can provide supplemental support, including:
Your Otezla patients can enroll in the Amgen Nurse Partner Program online at https://www.otezla.com/enroll or by calling 1-844-4OTEZLA (1-844-468-3952).
Amgen® Nurse Partners are only available to patients that are prescribed certain Amgen products. They are not part of your treatment team and do not provide medical advice, nursing, or case management services. Amgen® Nurse Partners will not inject patients with Amgen medications. Patients should always consult their healthcare provider regarding medical decisions or treatment concerns.
ContraindicationsOtezla is contraindicated in patients with a known hypersensitivity to apremilast or to any of the excipients in the formulation
Warnings and PrecautionsHypersensitivity: Hypersensitivity reactions, including angioedema and anaphylaxis, have been reported during postmarketing surveillance. If signs or symptoms of serious hypersensitivity reactions occur, discontinue Otezla and institute appropriate therapy
Warnings and Precautions
Use in Specific Populations
Please click here for the full Prescribing Information.
Otezla® (apremilast) is indicated for the treatment of adult patients with plaque psoriasis who are candidates for
phototherapy or systemic therapy.
Otezla is indicated for the treatment of adult patients with active psoriatic arthritis.
Otezla is indicated for the treatment of adult patients with oral ulcers associated with Behçet’s Disease.
Reference: 1. Data on file, Amgen Inc.